Phase I Study of In Vivo CAR-Tumor Technology for the Treatment of Advanced Malignant Tumors

The requested reference [82d93970c79e4fcce78c938a49d6e19b32cc3cca] no longer exists in our database. It has been replaced by the current reference: [56d9ddcde95f8f3c6ab98f999aec162202111372]

Authors Cancer Institute and Hospital, Chinese Academy of Medical Sciences -More
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
Links ClinicalTrials.gov
This study is a single-arm, open-label, dose-escalation platform clinical trial designed to evaluate the safety, tolerability, efficacy, pharmacokinetic and pharmacodynamic characteristics of CAR-Tumour oncolytic virus as a vector platform for the treatment of advanced malignant tumours. Subjects will be screened and assigned to cohorts based on target and indication: Cohort A: Intratumoural injection or intravenous injection of CAR-Tumor05 solution for the treatment of advanced malignant solid tumours Co-group B: Intratumoural injection, intravenous injection, subcutaneous injection, intramuscular injection, pleural perfusion, and intraperitoneal perfusion of CAR-Tumor05 injection for the treatment of advanced malignant solid tumours Co-group C: Intratumoural injection, intravenous injection, subcutaneous injection, intramuscular injection, pleural perfusion, and intraperitoneal perfusion of CAR-Tumor M01 injection for the treatment of advanced malignant solid tumours
Epistemonikos ID: 69391cad5ea73011b98447b9901ae497fb073078
First added on: Oct 06, 2026